Nodality, Inc. and Pfizer have entered a strategic collaboration for the use of Nodality’s Single Cell Network Profiling (SCNP) technology for the development of Pfizer compounds. The multi-year agreement will focus on providing biological bases for streamlining the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis, and drug profiling. Pfizer also has the option to partner with Nodality in companion diagnostics development. The agreement includes an upfront payment, R&D funding, and success-based milestone payments, but terms were not disclosed.
Michael Goldberg, executive chairman and interim chief executive officer of Nodality, said, “We are excited to be working with Pfizer’s world-class autoimmune R&D groups to enhance their drug development activities. This collaboration, which is Nodality’s second major strategic pharma partnership this year, provides continuing validation of the value the SCNP platform technology can bring to drug development. We look forward to a productive and collaborative relationship with Pfizer’s R&D teams."
Jose-Carlos Gutierrez-Ramos, senior vice president, BioTherapeutics R&D at Pfizer, said, “Our partnership with Nodality exemplifies Pfizer’s commitment to Precision Medicine by providing us with earlier insight into a compound’s potential clinical profile, which can help reduce attrition rates, accelerate development and improve patient targeting. There is a tremendous patient need for new medicines that can impact the pathophysiology of autoimmune diseases.”